Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer
Conclusion: From a societal perspective, our cost-effectiveness results support the value of multiplexed genetic screening and molecularly guided therapy in metastatic NSCLC.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Original Articles Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer